The Innovative Wachstumskern PRAEMED.Bio is a project funded by the BMBF with a duration of 3 years 01.01.2019 - 31.12.2021. Companies and research institutions like attomol GmbH, GA Generic Assay, Brandenburg Technical University Cottbus-Senftenberg, PolyAn GmbH, German Consortium for Translational Cancer Research, Technical University Dresden- Immunology, Institute for Clinical Chemistry and Laboratory Medicine of the University Hospital Carl Gustav Carus in Dresden, Gesellschaft für medizinische und wissenschaftliche genetische Analysen Dresden mbH (Mewigen), Lipotype GmbH, Medipan GmbH, Cybertron GmbH, KDS Radeberger Werkzeugbau GmbH and Resintec GmbH cooperate with each other.